Prevalence of Primary Aldosteronism in Patients With Resistant Hypertension in China
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01459042
Recruitment Status :
First Posted : October 25, 2011
Last Update Posted : October 25, 2011
Shanghai Jiao Tong University School of Medicine
Information provided by (Responsible Party):
Wang Weiqing, Shanghai Jiao Tong University School of Medicine
Recent studies indicate that primary aldosteronism (PA) is a much more common cause of hypertension than had been demonstrated historically. In patients with resistant hypertension, the prevalence of PA from different clinics worldwide is about 10-20%. As has been no such data in China, the investigators are conducting a PA study in different province of China to evaluate the prevalence of PA in patients with resistant hypertension.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with resistant hypertension from different provinces of China
patients with resistant hypertension
age 18-65 years
known cause of hypertension
Stroke, transient ischaemic attack or myocardial infarction in the past 6 months